In-vivo subdermal implant in the alpha-Gal knockout mice model for the assessment of bioprosthetic heart valve calcification rate before and after a polyphenols-based treatment

Rationale The presence of preformed antibodies against αGal in the human lead to opsonization of the implanted bioprosthetic heart valve (BHV), leading to deterioration and calcification. Murine subcutaneous implantation of BHVs leaflets has been widely used for testing the efficacy of anti-calcification treatments, however, unlike the situation in humans, leaflets implanted into a murine model will not be able to elicit an αGal immune response because both donor and recipient species constitutively express the epitope. Objective This study evaluates the calcium deposition on commercial BHV using a new humanized murine αGal knockout (KO) animal model. Furtherly, the anti-calcification efficacy of a polyphenol-based treatment was deeply investigated. Methods and Results By using CRISPR/Cas9 approach an αGal KO mouse was created and used for the evaluation of the calcific propensity of original and polyphenols-treated BHV by subcutaneous implantation. The calcium quantification was carried out by plasma analysis; the immune response evaluation was performed by histology and immunological assays. Anti-αGal antibodies level in KO mice increases at least double after 2 months of implantation of original commercial BHV compared to WT mice, conversely, the polyphenols-based treatment seems to effectively mask the antigen to the KO mice’s immune system. Commercial leaflets explanted after 1 month from KO mice showed a four-time increased calcium deposition than what was observed on that explanted from WT. Polyphenol treatment prevents calcium deposition by over 99% in both KO and WT animals. Conclusions The implantation of commercial BHV leaflets significantly stimulates the KO mouse immune system resulting in massive production of anti-Gal antibodies and the exacerbation of the αGal-related calcific effect if compared with the WT mouse. The polyphenol-based treatment applied in this investigation showed an unexpected ability to inhibit the recognition of BHV xenoantigens by circulating antibodies completely preventing calcific depositions compared to the untreated counterpart.

[1]  F. Nicotra,et al.  Preventing extrinsic mechanisms of bioprosthetic degeneration using polyphenols. , 2022, European Journal of Cardio-Thoracic Surgery.

[2]  R. Melder,et al.  Polyphenols could be Effective in Exerting a Disinfectant-Like Action on Bioprosthetic Heart Valves, Counteracting Bacterial Adhesiveness , 2022, Cardiology and cardiovascular medicine.

[3]  G. Gerosa,et al.  The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration , 2022, Nature Medicine.

[4]  M. Wenk,et al.  A reference map of sphingolipids in murine tissues. , 2021, Cell reports.

[5]  J. Cornish,et al.  Subcutaneous Surgical Rat Models for the Evaluation of Tissue-Engineered Heart Valve Immunogenicity: A Systematic Review , 2021, SSRN Electronic Journal.

[6]  A. Kutikhin,et al.  Degeneration of Bioprosthetic Heart Valves: Update 2020 , 2020, Journal of the American Heart Association.

[7]  M. Dweck,et al.  Pathophysiology of Aortic Stenosis and Future Perspectives for Medical Therapy. , 2020, Cardiology clinics.

[8]  F. Schoen,et al.  Preclinical Assessment of Cardiac Valve Substitutes: Current Status and Considerations for Engineered Tissue Heart Valves , 2019, Front. Cardiovasc. Med..

[9]  Z. Tobota,et al.  Trends in isolated aortic valve replacement in middle‐aged patients over the last 10 years: epidemiology, risk factors, valve pathology, valve types, and outcomes , 2019 .

[10]  A. Gandaglia,et al.  Alpha-Gal Inactivated Heart Valve Bioprostheses Exhibit an Anti-Calcification Propensity Similar to Knockout Tissues. , 2017, Tissue engineering. Part A.

[11]  METHOD FOR INACTIVATING XENOANTIGENS IN BIOLOGICAL TISSUES The present invention relates to a method for inactivating xenoantigens in biological tissues, in particular for inactivating xenoantigens in tissues that can , 2017 .

[12]  F. Platt,et al.  Silencing the porcine iGb3s gene does not affect Galα3Gal levels or measures of anticipated pig‐to‐human and pig‐to‐primate acute rejection , 2016, Xenotransplantation.

[13]  G. Heinze,et al.  Suitability of the Rat Subdermal Model for Tissue Engineering of Heart Valves , 2014, Medical science monitor basic research.

[14]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[15]  M. Antunes,et al.  Low-dose acetyl salicylic acid versus oral anticoagulation after bioprosthetic aortic valve replacement. Final report of the ACTION registry. , 2013, International journal of cardiology.

[16]  G. Gerosa,et al.  First quantification of alpha‐Gal epitope in current glutaraldehyde‐fixed heart valve bioprostheses , 2013, Xenotransplantation.

[17]  Yong Jin Kim,et al.  Immune response to bovine pericardium implanted into α1,3-galactosyltransferase knockout mice: feasibility as an animal model for testing efficacy of anticalcification treatments of xenografts. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[18]  Alain Carpentier,et al.  Cardiac xenotransplantation technology provides materials for improved bioprosthetic heart valves. , 2011, The Journal of thoracic and cardiovascular surgery.

[19]  Alain Carpentier,et al.  Gal knockout pig pericardium: new source of material for heart valve bioprostheses. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  K. Hoetzenecker,et al.  Alpha-Gal Specific IgG Immune Response after Implantation of Bioprostheses , 2009, The Thoracic and cardiovascular surgeon.

[21]  A. D'apice,et al.  Anti‐Gal antibody‐mediated skin graft rejection requires a threshold level of Gal expression , 2008, Xenotransplantation.

[22]  K. Feingold The role of epidermal lipids in cutaneous permeability barrier homeostasis , 2007 .

[23]  M. Sandrin,et al.  The molecular basis for galalpha(1,3)gal expression in animals with a deletion of the alpha1,3galactosyltransferase gene. , 2006, Journal of immunology.

[24]  E. Wolner,et al.  Presence and elimination of the xenoantigen gal (alpha1, 3) gal in tissue-engineered heart valves. , 2005, Tissue engineering.

[25]  W. Klepetko,et al.  Alpha‐Gal on bioprostheses: xenograft immune response in cardiac surgery , 2005, European journal of clinical investigation.

[26]  D. Sachs,et al.  Marked prolongation of porcine renal xenograft survival in baboons through the use of α1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue , 2005, Nature Medicine.

[27]  N. Mueller,et al.  Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience , 2005, Nature Medicine.

[28]  E Wolner,et al.  Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[29]  P. Zilla,et al.  Characterization of the immune response to valve bioprostheses and its role in primary tissue failure. , 2001, The Annals of thoracic surgery.

[30]  P. Zilla,et al.  Inflammatory and immune processes: the neglected villain of bioprosthetic degeneration? , 2001, Journal of long-term effects of medical implants.

[31]  U. Galili,et al.  Adult and neonatal anti‐Gal response in knock‐out mice for α1,3galactosyltransferase , 1998, Xenotransplantation.

[32]  A. Robins,et al.  The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. , 1996, Transplantation.

[33]  K. Gustafsson,et al.  cDNA sequence and chromosome localization of pig alpha 1,3 galactosyltransferase. , 1995, Immunogenetics.

[34]  U. Galili,et al.  A Unique Natural Human Igg Antibody with Anti-a-galactosyl Specificity , 2022 .

[35]  W. Norton,et al.  Isolation and Characterization of Myelin , 1977 .

[36]  B. Carabello,et al.  Aortic stenosis , 2018, Rapid Cardiac Care.